SEC Tracker
Get the app

BeyondSpring BYSI

BeyondSpring Q2 FY25: net loss $1.8M; diluted EPS −$0.10

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers BeyondSpring reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$1.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.10No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$9.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$5.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when BeyondSpring files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025
  2. Seres Therapeutics MCRB public float $72M, Jun 30, 2025
  3. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  4. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  5. Volitionrx VNRX public float $73M, Jun 30, 2025